Cardiff Oncology Appoints Interim CMO Following Departure, Increases Authorized Shares

Cardiff Oncology announced a leadership transition in its clinical team and an amendment to its corporate charter. The company's Chief Medical Officer, Dr. Roger Sidhu, has departed, and Dr. Leila Alland has been appointed as interim Chief Medical Officer. Separately, the company has increased its total number of authorized common stock shares.

Key Details

• Management Change: Dr. Roger Sidhu separated from his role as Chief Medical Officer on October 22, 2026. Dr. Leila Alland was appointed interim CMO effective October 23, 2026, under a consulting agreement with a monthly fee of $35,000, effective until at least April 22, 2027.
• Increased Authorized Shares: On October 22, 2026, the company filed an amendment to its Certificate of Incorporation to increase the authorized number of shares of common stock to 300,000,000.
• Clinical Context: The leadership change occurs as Cardiff prepares to initiate a registrational Phase 3 study for its lead asset, onvansertib, in the first quarter of 2027.